BeiGene, Ltd. (HKG:6160)
Market Cap | 229.95B |
Revenue (ttm) | 29.60B |
Net Income (ttm) | -5.01B |
Shares Out | n/a |
EPS (ttm) | -47.57 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 5,704,360 |
Average Volume | 5,158,358 |
Open | 162.30 |
Previous Close | 164.90 |
Day's Range | 159.00 - 166.20 |
52-Week Range | 75.45 - 178.00 |
Beta | 0.65 |
RSI | 58.20 |
Earnings Date | May 14, 2025 |
About BeiGene
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo... [Read more]
Financial Performance
In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.
Financial numbers in USD Financial StatementsNews
BeiGene slips on decision to halt lung cancer program

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...

China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for ... Full story available on Benzinga.com
BeiGene wins FDA nod for Tevimbra in first-line esophageal cancer
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Q4 2024 Beigene Ltd Earnings Presentation Transcript
Q4 2024 Beigene Ltd Earnings Presentation Transcript
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript
BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion
BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion
BeiGene reports Q4 results

Hang Seng Index left untouched, but tweaks made to tech, China enterprises indices
Tencent Music and Horizon Robotics added to Hang Seng Tech Index, while ZTO Express and BeiGene added to Hang Seng China Enterprises Index.
BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook
BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook

ImmunityBio announces collaboration with Beigene
ImmunityBio partners with BeiGene for Phase 3 trial combining tislelizumab and ANKTIVA to improve survival in non-small cell lung cancer patients.
BeiGene Stock Meets 80-Plus RS Rating Benchmark
BeiGene ADR sees its Relative Strength Rating move into the 80-plus level.

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
BASEL, Switzerland--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appoi...
BeiGene (BGNE) Stock Rises on FDA Approval for Cancer Treatment
BeiGene (BGNE) Stock Rises on FDA Approval for Cancer Treatment
BeiGene wins FDA nod for Tevimbra in gastric cancer

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...
BeiGene (BGNE) Announces Ticker Change to ONC Effective January 2025
BeiGene (BGNE) Announces Ticker Change to ONC Effective January 2025
BeiGene Ltd (BGNE) Announces Ticker Symbol Change to "ONC" in 2025
BeiGene Ltd (BGNE) Announces Ticker Symbol Change to "ONC" in 2025

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announ...
BeiGene Ltd (BGNE) Announces Global Licensing Agreement for Novel Cancer Treatment
BeiGene Ltd (BGNE) Announces Global Licensing Agreement for Novel Cancer Treatment

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...
Baker Bros. Advisors LP's Strategic Acquisition of BeiGene Ltd Shares
Baker Bros. Advisors LP's Strategic Acquisition of BeiGene Ltd Shares
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, furthe...

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today an...